Literature DB >> 7974621

Carisoprodol elimination in humans.

H Olsen1, E Koppang, G Alvan, J Mørland.   

Abstract

The elimination of the muscle relaxant drug, carisoprodol, was examined in 10 healthy volunteers after an oral dose of 700 mg. In nine subjects, carisoprodol was rapidly eliminated, with a mean half-life of 99 +/- 46 min, and extensively converted to meprobamate. Within 2.5 h after carisoprodol intake, meprobamate serum concentrations exceeded those of carisoprodol. Serum levels of meprobamate recorded (15-25 mumol/L) indicate that meprobamate might contribute to the effect(s) of carisoprodol. One subject eliminated carisoprodol with an overall half-life of 376 min, and only small amounts of meprobamate were recorded. This subject was found to be a poor metabolizer of mephenytoin. In spiked human sera, protein binding of carisoprodol was in the range of 41-67%, whereas meprobamate was bound to a lesser extent, 14-24%.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974621     DOI: 10.1097/00007691-199408000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  16 in total

1.  Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors.

Authors:  Manish Kumar; Glenn H Dillon
Journal:  Eur J Pharmacol       Date:  2016-02-09       Impact factor: 4.432

2.  Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003.

Authors:  Gudrun Høiseth; Jørgen G Bramness; Asbjørg S Christophersen; Jørg Mørland
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

3.  The effect of stress on absorption of acetaminophen.

Authors:  Magne Arve Flaten; Ole Asli; Terje Simonsen
Journal:  Psychopharmacology (Berl)       Date:  2006-03-16       Impact factor: 4.530

4.  Carisoprodol pharmacokinetics and distribution in the nucleus accumbens correlates with behavioral effects in rats independent from its metabolism to meprobamate.

Authors:  Theresa M Carbonaro; Vien Nguyen; Michael J Forster; Michael B Gatch; Laszlo Prokai
Journal:  Neuropharmacology       Date:  2020-05-29       Impact factor: 5.250

5.  Overdose of meprobamate: plasma concentration and Glasgow Coma Scale.

Authors:  Anne-Claire Buire; Fabien Vitry; Guillaume Hoizey; Denis Lamiable; Thierry Trenque
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

6.  Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-08-23       Impact factor: 3.533

7.  Carisoprodol tolerance and precipitated withdrawal.

Authors:  Michael B Gatch; Jacques D Nguyen; Theresa Carbonaro; Michael J Forster
Journal:  Drug Alcohol Depend       Date:  2011-11-04       Impact factor: 4.492

Review 8.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

9.  Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma.

Authors:  Gunchan Paul; Gautam L Parshotam; Rajneesh Garg
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jul-Sep

Review 10.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.